GlassScriptPhysician profile
Marcus L Simmons
NPI 1770511180
$3,760.16
in general payments reported to CMS, 2019-2025
36 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $842 · 2021: $507 · 2022: $583 · 2023: $623 · 2024: $339 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $451.44 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $293.78 | 2019-2023 | Verquvo, Belsomra |
| Novo Nordisk INC | $286.75 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $275.78 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $253.85 | 2021-2024 | Vraylar |
| Pfizer INC. | $226.66 | 2019-2025 | |
| Glaxosmithkline, LLC. | $201.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $195.73 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $172.52 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $151.78 | 2019-2021 | |
| Lilly USA, LLC | $145.70 | 2021-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.81 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $117.80 | 2019-2023 | |
| Abbott Laboratories | $102.22 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $84.33 | 2019-2024 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.04 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $60.20 | 2019 | |
| Ironwood Pharmaceuticals, INC | $52.36 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $50.29 | 2020-2021 | |
| Esperion Therapeutics, INC. | $49.15 | 2021-2023 | Nexletol |
| Halozyme INC | $44.44 | 2023 | |
| Sanofi-Aventis U.S. LLC | $39.09 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.84 | 2023 | Takhzyro |
| Exact Sciences Corporation | $34.75 | 2024 | Cologuard Collection Kit |
| Antares Pharma, INC. | $25.66 | 2024 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $23.51 | 2020 | |
| Vifor Pharma, INC. | $23.42 | 2023 | Veltassa |
| Teva Pharmaceuticals USA, INC. | $22.65 | 2019 | |
| Endo Pharmaceuticals INC. | $21.13 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.76 | 2022 | |
| Eisai INC. | $18.70 | 2020 | |
| Astellas Pharma US INC | $17.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.88 | 2022 | |
| Hikma Pharmaceuticals USA | $15.96 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.14 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.